Measurement of affective state during chronic nicotine treatment and withdrawal by affective taste reactivity in mice: The role of endocannabinoids

Biochemical Pharmacology

Volumn 78, Issue 7, 2009, Pages 825-835

  Wing, Victoria C ^a   Cagniard, Barbara ^b   Murphy, Niall P ^b   Shoaib, Mohammed ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

Affective state; Endocannabinoids; Mouse; Nicotine; Taste reactivity; Withdrawal

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ENDOCANNABINOID; NICOTINE; QUININE; SUCROSE;

AFFECT; ANIMAL EXPERIMENT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSORY STIMULATION; SMOKING CESSATION; STIMULUS RESPONSE; TASTE;

AFFECT; ANIMALS; AVOIDANCE LEARNING; ENDOCANNABINOIDS; MALE; MICE; MICE, INBRED C57BL; NICOTINE; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SUBSTANCE WITHDRAWAL SYNDROME; TASTE; TOBACCO USE DISORDER;

EID: 68349127239     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.06.017     Document Type: Article

References (78)

1. Perkins K.A., Grobe J.E., Fonte C., Goettler J., Caggiula A.R., Reynolds W.A., et al. Chronic and acute tolerance to subjective, behavioral and cardiovascular effects of nicotine in humans. J Pharmacol Exp Ther 270 (1994) 628-638
2. Gommans J., Stolerman I.P., and Shoaib M. Antagonism of the discriminative and aversive stimulus properties of nicotine in C57BL6J mice. Neuropharmacology 39 (2000) 2840-2847
3. Sanchis-Segura C., and Spanagel R. Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addict Biol 11 (2006) 2-38
4. Huston-Lyons D., and Kornetsky C. Effects of nicotine on the threshold for rewarding brain stimulation in rats. Pharmacol, Biochem Behav 41 (1992) 755-759
5. Fudala P.J., Teoh K.W., and Iwamoto E.T. Pharmacologic characterization of nicotine-induced conditioned place preference. Pharmacol, Biochem Behav 22 (1985) 237-241
6. Fudala P.J., and Iwamoto E.T. Further studies on nicotine-induced conditioned place preference in the rat. Pharmacology. Biochem Behav 25 (1986) 1041-1049
7. Clarke P.B., and Fibiger H.C. Apparent absence of nicotine-induced conditioned place preference in rats. Psychopharmacology 92 (1987) 84-88
8. Le Foll B., and Goldberg S.R. Nicotine induces conditioned place preferences over a large range of doses in rats. Psychopharmacology 178 (2005) 481-492
9. Iwamoto E.T., and Williamson E.C. Nicotine-induced taste aversion: characterization and preexposure effects in rats. Pharmacol, Biochem Behav 21 (1984) 527-532
10. Shoaib M., and Stolerman I.P. The NMDA antagonist dizocilpine (MK801) attenuates tolerance to nicotine in rats. J Psychopharmacol 10 (1996) 214-218
11. Hughes J.R., Gulliver S.B., Fenwick J.W., Valliere W.A., Cruser K., Pepper S., et al. Smoking cessation among self-quitters. Health Psychol 11 (1992) 331-334
12. Shiffman S.M., and Jarvik M.E. Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology 50 (1976) 35-39
13. Hughes J.R., Gust S.W., Skoog K., Keenan R.M., and Fenwick J.W. Symptoms of tobacco withdrawal. A replication and extension. Arch Gen Psychiatry 48 (1991) 52-59
14. Hughes J.R., and Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43 (1986) 289-294
15. Markou A., Kosten T.R., and Koob G.F. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 18 (1998) 135-174
16. Koob G.F., Caine S.B., Parsons L., Markou A., and Weiss F. Opponent process model and psychostimulant addiction. Pharmacol, Biochem Behav 57 (1997) 513-521
17. Le Foll B., Forget B., Aubin H.-J., and Goldberg S.R. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol 13 (2008) 239-252
18. Gonzalez S., Cascio M.G., Fernandez-Ruiz J., Fezza F., Di Marzo V., and Ramos J.A. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 954 (2002) 73-81
19. Shoaib M. The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology 54 (2008) 438-444
20. Cohen C., Perrault G., Griebel G., and Soubrie P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 30 (2005) 145-155
21. Cohen C., Perrault G., Voltz C., Steinberg R., and Soubrie P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13 (2002) 451-463
22. Le Foll B., and Goldberg S.R. Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport 15 (2004) 2139-2143
23. Castane A., Valjent E., Ledent C., Parmentier M., Maldonado R., and Valverde O. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 43 (2002) 857-867
24. Cahill K, Ussher M. Cannabinoid type 1 receptor anatagonists (rimonabant) for smoking cessation. The Cochrane Library; 2008.
25. Witkin J.M., Tzavara E.T., and Nomikos G.G. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol 16 (2005) 315-331
26. Berridge K.C. Measuring hedonic impact in animals and infants: microstructure of affective taste reactivity patterns. Neurosci Biobehav Rev 24 (2000) 173-198
27. Rideout H.J., and Parker L.A. Morphine enhancement of sucrose palatability: analysis by the taste reactivity test. Pharmacol, Biochem Behav 53 (1996) 731-734
28. Doyle T.G., Berridge K.C., and Gosnell B.A. Morphine enhances hedonic taste palatability in rats. Pharmacol, Biochem Behav 46 (1993) 745-749
29. Parker L.A., Maier S., Rennie M., and Crebolder J. Morphine- and naltrexone-induced modification of palatability: analysis by the taste reactivity test. Behav Neurosci 106 (1992) 999-1010
30. Clarke S.N., and Parker L.A. Morphine-induced modification of quinine palatability: effects of multiple morphine-quinine trials. Pharmacol, Biochem Behav 51 (1995) 505-508
31. Parker L., and Leeb K. Amphetamine-induced modification of quinine palatability: analysis by the taste reactivity test. Pharmacol, Biochem Behav 47 (1994) 413-420
32. Kenny P.J., and Markou A. Neurobiology of the nicotine withdrawal syndrome. Pharmacol, Biochem Behav 70 (2001) 531-549
33. Gatley S.J., Lan R., Pyatt B., Gifford A.N., Volkow N.D., and Makriyannis A. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci 61 (1997) PL191-PL197
34. Wing VC, Shoaib M. A second order schedule of nicotine reinforcement in the rat to examine the role of endocannabinoids, submitted for publication.
35. Damaj M.I., Kao W., and Martin B.R. Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J Pharmacol Exp Ther 307 (2003) 526-534
36. Davis J.A., and Gould T.J. Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning. Neuropsychopharmacology 32 (2007) 2011-2019
37. Corbille A.-G., Valjent E., Marsicano G., Ledent C., Lutz B., Herve D., et al. Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. J Neurosci 27 (2007) 6937-6947
38. Haller J., Matyas F., Soproni K., Varga B., Barsy B., Nemeth B., et al. Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur J Neurosci 25 (2007) 2445-2456
39. Cagniard B., and Murphy N. Taste reactivity and its modulation by morphine and methamphetamine in C57BL6 and DBA/2 mice. Physiol Behav 96 (2009) 412-420
40. Kiefer S.W., Hill K.G., and Kaczmarek H.J. Taste reactivity to alcohol and basic tastes in outbred mice. Alcohol: Clin Exp Res 22 (1998) 1146-1151
41. Pecina S., and Berridge K.C. Hedonic hot spot in nucleus accumbens shell: where do mu-opioids cause increased hedonic impact of sweetness?. J Neurosci 25 (2005) 11777-11786
42. Mahler S.V., Smith K.S., and Berridge K.C. Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward. Neuropsychopharmacology 32 (2007) 2267-2278
43. Pecina S., Cagniard B., Berridge K.C., Aldridge J.W., and Zhuang X. Hyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet rewards. J Neurosci 23 (2003) 9395-9402
44. Marks M.J., Stitzel J.A., and Collins A.C. Genetic influences on nicotine responses. Pharmacol, Biochem Behav 33 (1989) 667-678
45. Damaj M.I., Welch S.P., and Martin B.R. Characterization and modulation of acute tolerance to nicotine in mice. J Pharmacol Exp Ther 277 (1996) 454-461
46. Damaj M.I., Welch S.P., and Martin B.R. In vivo pharmacological effects of dihydro-beta-erythroidine, a nicotinic antagonist, in mice. Psychopharmacology 117 (1995) 67-73
47. Valjent E., Mitchell J.M., Besson M.J., Caboche J., and Maldonado R. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol 135 (2002) 564-578
48. McLaughlin P.J., Winston K., Swezey L., Wisniecki A., Aberman J., Tardif D.J., et al. The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 14 (2003) 583-588
49. Parker L.A., and Doucet K. The effects of nicotine and nicotine withdrawal on taste reactivity. Pharmacol, Biochem Behav 52 (1995) 125-129
50. Marks M.J., Miner L., Burch J.B., Fulker D.W., and Collins A.C. A diallel analysis of nicotine-induced hypothermia. Pharmacol, Biochem Behav 21 (1984) 953-959
51. Itzhak Y., and Martin J.L. Effects of cocaine, nicotine, dizocipline and alcohol on mice locomotor activity: cocaine-alcohol cross-sensitization involves upregulation of striatal dopamine transporter binding sites. Brain Res 818 (1999) 204-211
52. Marks M.J., Burch J.B., and Collins A.C. Genetics of nicotine response in four inbred strains of mice. J Pharmacol Exp Ther 226 (1983) 291-302
53. Marks M.J., Burch J.B., and Collins A.C. Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharmacol Exp Ther 226 (1983) 817-825
54. Epping-Jordan M.P., Watkins S.S., Koob G.F., and Markou A. Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393 (1998) 76-79
55. Koob G.F. Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 56 Suppl. 1 (2009) 18-31
56. Malin D.H., Lake J.R., Carter V.A., Cunningham J.S., Hebert K.M., Conrad D.L., et al. The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. Psychopharmacology 115 (1994) 180-184
57. Hildebrand B.E., Nomikos G.G., Bondjers C., Nisell M., and Svensson T.H. Behavioral manifestations of the nicotine abstinence syndrome in the rat: peripheral versus central mechanisms. Psychopharmacology 129 (1997) 348-356
58. Suzuki T., Ise Y., Tsuda M., Maeda J., and Misawa M. Mecamylamine-precipitated nicotine-withdrawal aversion in rats. Eur J Pharmacol 314 (1996) 281-284
59. Helton D.R., Modlin D.L., Tizzano J.P., and Rasmussen K. Nicotine withdrawal: a behavioral assessment using schedule controlled responding, locomotor activity, and sensorimotor reactivity. Psychopharmacology 113 (1993) 205-210
60. Costall B., Kelly M.E., Naylor R.J., and Onaivi E.S. The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacol, Biochem Behav 33 (1989) 197-203
61. Mannucci C., Tedesco M., Bellomo M., Caputi A.P., and Calapai G. Long-term effects of nicotine on the forced swimming test in mice: an experimental model for the study of depression caused by smoke. Neurochem Int 49 (2006) 481-486
62. Hughes J.R., and Hughes J.R. Effects of abstinence from tobacco: valid symptoms and time course. [see comment]. Nicotine Tob Res 9 (2007) 315-327
63. Isola R., Vogelsberg V., Wemlinger T.A., Neff N.H., and Hadjiconstantinou M. Nicotine abstinence in the mouse. Brain Res 850 (1999) 189-196
64. Jonkman S., Henry B., Semenova S., and Markou A. Mild anxiogenic effects of nicotine withdrawal in mice. Eur J Pharmacol 516 (2005) 40-45
65. Johnson P.M., Hollander J.A., and Kenny P.J. Decreased brain reward function during nicotine withdrawal in C57BL6 mice: Evidence from intracranial self-stimulation (ICSS) studies. Pharmacol, Biochem Behav 90 (2008) 409-415
66. Stoker A.K., Semenova S., and Markou A. Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL6J and BALB/cByJ mice. Neuropharmacology 54 (2008) 1223-1232
67. Portugal G.S., and Gould T.J. Nicotine withdrawal disrupts new contextual learning. Pharmacol, Biochem Behav 92 (2009) 117-123
68. Rauhut A.S., Hawrylak M., and Mardekian S.K. Bupropion differentially alters the aversive, locomotor and rewarding properties of nicotine in CD-1 mice. Pharmacol, Biochem Behav 90 (2008) 598-607
69. Tammimaki A., Chistyakov V., Patkina N., Skippari J., Ahtee L., Zvartau E., et al. Effect of forced chronic oral nicotine exposure on intravenous self-administration and rewarding properties of acute nicotine. Eur J Pharmacol 591 (2008) 164-170
70. Caggiula A.R., Donny E.C., Chaudhri N., Perkins K.A., Evans-Martin F.F., and Sved A.F. Importance of nonpharmacological factors in nicotine self-administration. Physiol Behav 77 (2002) 683-687
71. Caggiula A.R., Donny E.C., White A.R., Chaudhri N., Booth S., Gharib M.A., et al. Cue dependency of nicotine self-administration and smoking. Pharmacol, Biochem Behav 70 (2001) 515-530
72. Conklin C.A. Environments as cues to smoke: implications for human extinction-based research and treatment. Exp Clin Psychopharmacol 14 (2006) 12-19
73. Wing V.C., and Shoaib M. Contextual stimuli modulate the extinction and reinstatement in rodents self-administering intravenous nicotine. Psychopharmacology 200 (2008) 357-365
74. Donny E.C., Chaudhri N., Caggiula A.R., Evans-Martin F.F., Booth S., Gharib M.A., et al. Operant responding for a visual reinforcer in rats is enhanced by noncontingent nicotine: implications for nicotine self-administration and reinforcement. [see comment]. Psychopharmacology 169 (2003) 68-76
75. Jarrett M.M., Scantlebury J., and Parker L.A. Effect of delta9-tetrahydrocannabinol on quinine palatability and AM251 on sucrose and quinine palatability using the taste reactivity test. Physiol Behav 90 (2007) 425-430
76. Jarrett M.M., Limebeer C.L., and Parker L.A. Effect of Delta9-tetrahydrocannabinol on sucrose palatability as measured by the taste reactivity test. Physiol Behav 86 (2005) 475-479
77. Fattore L., Fadda P., and Fratta W. Endocannabinoid regulation of relapse mechanisms. Pharmacol Res 56 (2007) 418-427
78. Berridge K.C., and Grill H.J. Isohedonic tastes support a two-dimensional hypothesis of palatability. Appetite 5 (1984) 221-231